Hepatitis C DNA vaccine - Merck & Co.

Drug Profile

Hepatitis C DNA vaccine - Merck & Co.

Alternative Names: HCV DNA vaccine - Merck & Co.

Latest Information Update: 30 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antivirals; DNA vaccines; Hepatitis C vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Research Hepatitis C

Most Recent Events

  • 30 Mar 2010 Research phase development is ongoing in USA
  • 07 Nov 2006 Preclinical trials in Hepatitis C prevention in USA (IM)
  • 27 Nov 2001 This compound is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top